Related Experiment Video
Updated: Jan 7, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Baicalin attenuates pulmonary hypertension by targeting AMPK/CPT1A-mediated fatty acid metabolism
Meihong Chen1, Yuan He2, Xiaoyun Zhu1
1Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong and Macao Region on Molecular Targets and Intervention of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China; Laboratory of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical University, Zhan-jiang, Guangdong 524001, China; Precision Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China.
Background:
Pulmonary hypertension (PH) is a life-threatening cardiopulmonary vascular disease, characterized by vascular remodeling due to the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs). Baicalin has shown therapeutic potential for PH. However, its underlying mechanism remains unclear.
Purpose:
The aim is to investigate the therapeutic potential and underlying mechanism of baicalin against PH.
Study Design:
Both in vivo and in vitro models of PH were employed. The in vivo model was established using Su5416 combined with hypoxia (SuHx), while the in vitro model involved hypoxia-induced PASMCs.
Methods:
We first evaluated the pharmacological effect of baicalin on disease progression using physiological and biochemical assessments. We then employed a comprehensive suite of techniques to elucidate its mechanisms of action, including transthoracic echocardiography, immunofluorescence, immunohistochemistry, flow cytometry, Western blot, molecular docking, surface plasmon resonance (SPR), network pharmacology, and transcriptomic analyses.
Results:
Baicalin treatment improved hemodynamic parameters and attenuated pulmonary vascular remodeling, right ventricular systolic pressure (RVSP), and right ventricular hypertrophy in SuHx-induced PH mice. It also inhibited hypoxia-induced proliferation and migration of PASMCs in vitro. Network pharmacology and transcriptomic analyses identified baicalin as a modulator of metabolic pathways, particularly fatty acids oxidation (FAO), with CPT1A as a key regulator. Baicalin inhibited AMPK phosphorylation and CPT1A expression, thereby reducing FAO activity and ATP production. Molecular docking and SPR studies confirmed strong binding between baicalin and AMPKα1, supporting its direct regulatory role.
Conclusions:
This study demonstrates that baicalin alleviates PH by modulating FAO through inhibition of the AMPK/CPT1A axis. Our findings provide evidence for the therapeutic efficacy of baicalin and elucidate its molecular mechanism, suggesting a promising therapeutic intervention for PH.
More Related Videos
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System